CANF CanFite Bio-Pharma stock accumulation

AMEX:CANF   Can-Fite Biopharma Ltd Sponsored
A succesful breakout of $2.50 could lead to $3.75
Not investment advice. Trade safely.
Can-Fite BioPharma Ltd . operates as a clinical-stage biopharmaceutical company, which focuses on developing orally bioavailable small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological and ophthalmic diseases. Its products include pipeline drugs such as CF101, CF102 and CF602. The company offers drugs for the treatment of Psoriasis, Rheumatic Arthritis, Glaucoma, Uveitis, Crohn's disease, Osteoathritis, Hepatitis C, and Liver Cancer.